Day: June 25, 2025

Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it has entered into a definitive agreement with Immedica Pharma AB (‘Immedica’), a leading global rare disease company, for the sale of its future royalties related to sales of ganaxolone outside of China. Under the terms of the agreement, Immedica will pay $7 million in cash to acquire 100% of the royalty rights held by Ovid, further strengthening Immedica’s focus on ganaxolone by acquiring control of additional intellectual property rights. This transaction provides a non-dilutive...

To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial in BPD MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on Wednesday, July 9, 2025 at 12:00 pm ET. The event, moderated by Michael Ropacki, PhD and Oryzon’s CMO for CNS, will feature insights from leading experts:Alan F. Schatzberg, MD, MS(Hon) – Stanford University School of Medicine Emil F. Coccaro, MD – The Ohio State University College of Medicine Eric Hollander, MD – Albert Einstein College of Medicine Sarah Fineberg, MD, PhD – Yale University School of MedicineThe event...

RICHMOND, Va., June 25, 2025 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO), a Fortune 500 company and one of the largest convenience store operators in the United States, proudly announces the opening of its first food-focused remodeled store in Ashland, Virginia, located at 10030 Sliding Hill Rd. This milestone location also marks the debut of fas craves, ARKO’s innovative new food brand that will be a key feature of future store remodels across its nationwide network. This flagship location is the first of eight initial sites—six remodels and two new-to-industry builds—launched as part of a pilot program focused on delivering a relevant and delicious menu of hot and cold grab-n-go items. The new concept debuts a crave-worthy prepared food and dispensed beverage concept designed for today’s on-the-go consumer. Whether it’s a quick...

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY), a net lease REIT focused on convenience and automotive retail real estate, will release its financial results for the second quarter ended June 30, 2025 after the market closes on Wednesday, July 23, 2025. Getty Realty Corp. will host a conference call and webcast on Thursday, July 24, 2025, at 8:30 a.m. EDT. To participate in the call, please dial 1-877-423-9813, or 1-201-689-8573 for international participants, ten minutes before the scheduled start. Participants may also access the call via live webcast by visiting the investors section of the Company’s website at ir.gettyrealty.com. If you cannot participate in the live event, a replay will be available on Thursday, July 24, 2025, beginning at 11:30 a.m. EDT through 11:59 p.m. EDT, Thursday, August...

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger Exercise of up to $7.6 million in Gross Proceeds from 2023 Financing Warrants Tied to FDA Acceptance of NDA for Review PRINCETON, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced the submission to the U.S. Food and Drug Administration (FDA) of the Company’s...

As shoppers shift to AI search, brands must optimize their data or risk missing opportunities to drive traffic and sales AUSTIN, Texas, June 25, 2025 (GLOBE NEWSWIRE) — BigCommerce (Nasdaq: BIGC), a leading open SaaS ecommerce platform for B2C and B2B businesses, and Feedonomics, a leading data feed management solution, today announced their customers now have access to cutting-edge AI-powered search engine Perplexity to optimize visibility and relevance for brands in AI search results. In the shift from traditional SEO to AI search, it is critical that merchants ensure their products can be syndicated to the right marketplaces and advertising channels or owned channels so they can be found in order to drive traffic and sales. Historical data scraping is inefficient and often inaccurate for large language models. Feedonomics now...

REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide choline) extended-release tablets, previously known as DCCR, at the 2025 United in Hope: International Prader-Willi Syndrome Conference. “We believe that these data reveal critical insights on the potential benefit of VYKAT XR to important subpopulations of individuals living with PWS,” said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. “For those individuals who are managed with strict food controls, these data suggest that they had more hyperphagia symptoms at baseline yet still saw a statistically significant, clinically meaningful...

MADRID and HOLMDEL, N.J., June 25, 2025 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication solutions, today announced that it has joined ISMS Forum, Spain’s leading cybersecurity association dedicated to promoting information security, data protection, and risk management best practices. This collaboration reinforces BIO-key’s expanding presence and commitment to enhancing cybersecurity resilience and contributing to the development of robust security strategies for organizations across Spain. Through its ISMS Forum membership, BIO-key will actively participate in a range of initiatives seeking to drive innovation in identity and access management, Zero Trust security, and regulatory compliance. BIO-key will:Collaborate with members...

WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that it has entered into a share purchase agreement (SPA) with Williamsburg Venture Holdings (WVH), an institutional investor. We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux Mediator™ VAR 200 to treat chronic kidney diseases. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research). The SPA allows ZyVersa to be judicious and plan for the timing and amount of any equity...

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen Based on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMACAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging...